<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01133496</url>
  </required_header>
  <id_info>
    <org_study_id>095-06</org_study_id>
    <nct_id>NCT01133496</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Alendronate Sodium Tablets 70 mg of Dr. Reddy's Under Fasting Conditions</brief_title>
  <official_title>Open Label, Balanced, Randomized, Two-way, Single-dose, Crossover Bioequivalence Study of Alendronate Sodium 70 mg Tablets of Dr Reddy's, India and Fosamax® Tablets of Merck &amp; Co., Inc., USA, in Healthy Subjects Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the bioequivalence of Alendronate Sodium 70 mg of&#xD;
      Dr. Reddy's and Fosamax Tablets 70 mg of Merck &amp; Co.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open label, balanced, randomized, two-treatment, two-sequence, two-period, single-dose,&#xD;
      crossover oral bioequivalence study of Alendronate sodium 70 mg tablets of Dr Reddy's&#xD;
      Laboratories Limited, India and Fosamax® tablets of Merck &amp; Co., Inc., USA, in healthy,&#xD;
      adult, human subjects under fasting conditions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">April 2007</completion_date>
  <primary_completion_date type="Actual">December 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence based on Cmax and AUC parameters</measure>
    <time_frame>5 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Alendronate Sodium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alendronate Sodium Tablets, 70 mg of Dr. Reddy's</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fosamax</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fosamax Tablets 70 mg of Merck &amp; Company. Inc., USA.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alendronate Sodium Tablets, 70 mg</intervention_name>
    <description>Alendronate Sodium Tablets, 70 mg of Dr. Reddy's Laboratories Limited.</description>
    <arm_group_label>Alendronate Sodium</arm_group_label>
    <arm_group_label>Fosamax</arm_group_label>
    <other_name>Fosamax Tablets 70 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy human subjects aged between 18 and 45 years (including both).&#xD;
&#xD;
          2. Subjects with a BMI between 18.5 - 24.9 Kg/m2 but weight not less than 45 Kgs.&#xD;
&#xD;
          3. Female subjects who are postmenopausal or surgically sterile.&#xD;
&#xD;
          4. Female subjects of child bearing potential practicing an acceptable method of birth&#xD;
             control for the duration of the study as judged by the investigator(s), such as&#xD;
             condoms, foams, jellies, diaphragm, intrauterine device (IUD) or abstinence.&#xD;
&#xD;
          5. Subjects with normal health as determined by personal medical history, clinical&#xD;
             examination, and laboratory examinations and serology tests.&#xD;
&#xD;
          6. Subjects having normal 12-lead electrocardiogram (ECG).&#xD;
&#xD;
          7. Subjects having normal chest X-Ray (P/A view).&#xD;
&#xD;
          8. Subjects able to communicate effectively.&#xD;
&#xD;
          9. Subjects willing to given written informed consent and adhere to all the requirements&#xD;
             of this protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects having contraindications or hypersensitivity to Alendronate sodium or related&#xD;
             drugs.&#xD;
&#xD;
          2. History or presence of any medical condition or disease according the opinion of the&#xD;
             physician.&#xD;
&#xD;
          3. History or presence of significant cardiovascular, pulmonary, hepatic, renal,&#xD;
             gastrointestinal, endocrine, immunological, dermatological, neurological or&#xD;
             psychiatric disease or disorder.&#xD;
&#xD;
          4. History or presence of significant alcoholism or drug abuse in the past one year.&#xD;
&#xD;
          5. History or presence of significant smoking (more than 10 cigarettes or beedi's/day or&#xD;
             consumption of tobacco products).&#xD;
&#xD;
          6. Difficulty with donating blood.&#xD;
&#xD;
          7. Difficulty in swallowing solids like tablets or capsules.&#xD;
&#xD;
          8. Systolic blood pressure less than 90 mm Hg or more than 140 mm Hg.&#xD;
&#xD;
          9. Diastolic blood pressure less than 60 mm Hg or more than 90 mm Hg.&#xD;
&#xD;
         10. Pulse rate less than 50/minute or more than 100/minute.&#xD;
&#xD;
         11. Use of any prescribed medication during last two weeks or OTC medical products during&#xD;
             the last one week preceding the first dosing.&#xD;
&#xD;
         12. Major illness during 3 months before screening.&#xD;
&#xD;
         13. Participation in a drug research study within past 3 months.&#xD;
&#xD;
         14. Donation of blood in the past 3 months before screening.&#xD;
&#xD;
         15. Female volunteers demonstrating a positive pregnancy screen.&#xD;
&#xD;
         16. Female volunteers who are currently breast-feeding.&#xD;
&#xD;
         17. Female volunteers with child bearing potential using prohibited contraceptive method&#xD;
             (Oral, Injectable or Implantable hormonal agents).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Naba Kr Talukdar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>GVK Biosciences Pvt. Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GVK Biosciences Pvt. Ltd.,</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500038</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <study_first_submitted>May 27, 2010</study_first_submitted>
  <study_first_submitted_qc>May 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2010</study_first_posted>
  <last_update_submitted>June 11, 2010</last_update_submitted>
  <last_update_submitted_qc>June 11, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 14, 2010</last_update_posted>
  <responsible_party>
    <name_title>Mr. Indu Bhushan/Senior Director - R&amp;D</name_title>
    <organization>Dr. Reddy's Laboratories Limited</organization>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>Alendronate Sodium</keyword>
  <keyword>crossover</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alendronate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

